HBHeather R. Burkin

Heather R. Burkin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Heather R. Burkin has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A bioprinted model of pregnant human uterine myometrium

    by Craig Ulrich, Korrina Siddiqui, Lexa K. Baldwin, Weijian Hua, Jacob K. Kuklok, Jada J. Okaikoi, Lauren L. Parker, Juli Petereit, Dave R. Quilici, Grace M. Silva, et al.

    Despite decades of research, complications associated with dysfunctional labor are leading causes of maternal and neonatal morbidity. Currently available experimental models are not sufficient to understand the complex mechanisms underlying human labor nor to test new therapeutic approaches. We sought to develop a bioprinted tissue model of pregnant human myometrium that replicates the morphological, contractile and molecular characteristics of native pregnant human uterine myometrium as a resource to accelerate basic discovery and pharmacological testing. We have utilized primary human uterine smooth muscle cells to bioprint myometrial tissue rings containing >75% viable cells with elongated, smooth muscle morphology. Immunofluorescence confirmed expression of smooth muscle markers (caldesmon, alpha smooth muscle actin, and smooth muscle myosin), contractile-associated proteins (oxytocin receptor, prostaglandin receptors and connexin-43), and steroid hormone receptors (estrogen and progesterone receptors) characteristic of pregnant human uterine myometrium. Bioprinted tissues contracted in response to physiological agonists oxytocin (p < 0.001), prostaglandin F 2α (p = 0.003), and prostaglandin E2 (p < 0.001), and relaxed in response to the nitric oxide donor S-nitrosoglutathione (p = 0.004). Further development of this model could provide an abundant and homogeneous tissue source to facilitate mechanistic studies and test agents to modulate labor.


  • Open Access

    Matrix Metallopeptidase 9 Promotes Contraction in Human Uterine Myometrium

    by Craig C. Ulrich, Lauren L. Parker, Janet A. Lambert, Lexa Baldwin, Iain L. O. Buxton, Neda Etezadi-Amoli, Normand Leblanc, Heather R. Burkin

    Matrix metallopeptidase 9 (MMP9) is a secreted zinc-dependent peptidase known for extracellular remodeling. MMP9 is elevated in tissues from women experiencing preterm labor, and previous research has shown that the addition of combined matrix metallopeptidases 2 and 9 (MMP2/9) enhances uterine contractions. We hypothesized that adding MMP9 alone would enhance myometrial contractions and that specific MMP9 inhibition would suppress uterine contractions. In myometrial tissue from women undergoing term Caesarean sections, we observed an increased contractile response as measured by area under the curve over time in tissues treated with MMP9 compared to vehicle-treated controls (p = 0.0003). This effect was primarily due to increased contraction frequency in MMP9-treated tissues compared to controls (p < 0.0001). Specific inhibition of MMP9 with the highly selective MMP9 inhibitor 1 (AG-L-66085) reduced contractile responses in myometrial tissues from pregnant women. We observed a reduction in the oxytocin-induced contractile response as measured by area under the curve over time (p < 0.0001) and contraction amplitude (p < 0.0068) in AG-L-66085-treated tissues compared to vehicle-treated controls. To determine the effects of MMP9 inhibition in the absence of exogenous oxytocin, we tested the effects of AG-L-66085 on spontaneous contractions. The area under the curve (p = 0.0415) and amplitude (p = 0.0354) of spontaneous contractions were reduced in response to 1 μM AG-L-66085, and the inhibitory effects increased as the AG-L-66085 concentration increased. Together, these data support the hypothesis that elevated MMP9 promotes myometrial contractions and labor, while its inhibition promotes relaxation.


  • Open Access

    Matrix metalloproteinases 2 and 9 are elevated in human preterm laboring uterine myometrium and exacerbate uterine contractility†

    by Craig C Ulrich, Veronica Arinze, Carolina Bueno Wandscheer, Christian Copley Salem, Camellia Nabati, Neda Etezadi-Amoli, Heather R Burkin

    Matrix metalloproteinases 2 and 9 (MMP2/9) have previously been shown to be elevated in serum and amniotic fluid from women undergoing preterm birth. We performed experiments to determine the effects of MMP2/9 on uterine contraction and birth timing. Pregnant mice were injected daily with 50 mg/kg of SB-3CT or vehicle control beginning on gestational day 14–18 to determine if MMP2/9 inhibition would affect parturition timing. MMP2/9 expression in human myometrial tissue was determined by Simple Western (Wes) and semiquantitative western blot. Purified MMP2/9 and SB-3CT inhibitor were added to human myometrial strips to determine the effects of MMP2/9 on oxytocin-induced uterine contraction. Parturition was delayed in mice treated with MMP2/9 inhibitor SB-3CT. MMP2/9 protein levels were elevated in preterm laboring uterine myometrium. Gelatinase activity was confirmed in cell extracts and supernatants from immortalized and primary human uterine myometrial cells in culture. Addition of purified MMP2/9 increased the oxytocin-induced contractile response in myometrial tissue strips from pregnant women. In contrast, addition of the MMP2/9 inhibitor SB-3CT decreased the contractile response to oxytocin in a dose-dependent manner. These results suggest abnormal MMP2/9 expression affects the contractile state of the uterine myometrium to promote parturition and that MMP2/9 inhibition attenuates this effect.


  • Mechanical strain induced phospho-proteomic signaling in uterine smooth muscle cells

    by Christian Copley Salem, Craig Ulrich, David Quilici, Karen Schlauch, Iain L.O. Buxton, Heather Burkin


  • Open Access

    Alternatively Spliced Human TREK-1 Variants Alter TREK-1 Channel Function and Localization1

    by Chad L. Cowles, Yi-Ying Wu, Scott D. Barnett, Michael T. Lee, Heather R. Burkin, Iain L.O. Buxton

    TREK-1, an outward-rectifying potassium channel activated by stretch, is found in the myometrium of pregnant women. Decreased expression of TREK-1 near term suggests that TREK-1 may contribute to uterine quiescence during gestation. Five alternatively spliced TREK-1 variants were identified in the myometrium of mothers who delivered spontaneously preterm (<37 wk), leading to the hypothesis that these TREK-1 variants could interfere with TREK-1 function or expression. To investigate a potential role for these variants, immunofluorescence, cell surface assays, Western blots, and patch clamp were employed to study TREK-1 and TREK-1 variants expressed in HEK293T cells. The results of this study demonstrate that coexpression of TREK-1 with TREK-1 variants alters TREK-1 expression and suppresses channel function. Each variant affected TREK-1 in a disparate manner. In HEK293T cells coexpressing TREK-1 and each variant, TREK-1 membrane expression was diminished with compartmentalization inside the cell. When expressed alone, individual variants displayed channel properties that were significantly decreased compared to full-length TREK-1. In coexpression studies using patch clamp, basal TREK-1 currents were reduced by ∼64% (4.3 vs. 12.0 pA/pF) on average at 0 mV when coexpressed with each variant. TREK-1 currents that were activated by intracellular acidosis were reduced an average of ∼77% (21.4 vs. 94.5 pA/pF) at 0 mV when cells were transfected with TREK-1 and any one of the splice variants. These data correlate the presence of TREK-1 variants to reduced TREK-1 activity, suggesting a pathological role for TREK-1 variants in preterm labor.


  • Open Access

    LC/MS/MS data analysis of the human uterine smooth muscle S-nitrosoproteome fingerprint in pregnancy, labor, and preterm labor

    by Craig C. Ulrich, David R. Quilici, Karen A. Schlauch, Heather R. Burkin, Iain L.O. Buxton

  • Open Access

    Blockade of extracellular NM23 or its endothelial target slows breast cancer growth and metastasis

    by Nucharee Yokdang, Senny Nordmeier, Katie Speirs, Heather R. Burkin, Iain L. O. Buxton

    OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.


  • Integrin Upregulation and Localization to Focal Adhesion Sites in Pregnant Human Myometrium

    by Heather R. Burkin, Monica Rice, Apurva Sarathy, Sara Thompson, Cherie A. Singer, Iain L. O. Buxton

    Focal adhesions are integrin-rich microdomains that structurally link the cytoskeleton to the extracellular matrix and transmit mechanical signals. In the pregnant uterus, increases in integrin expression and activation are thought to be critical for the formation of the mechanical syncytium required for labor. The aim of this study was to determine which integrins are upregulated and localized to focal adhesions in pregnant human myometrium. We used quantitative polymerase chain reaction, Western blotting, and confocal microscopy to determine the expression levels and colocalization with focal adhesion proteins. We observed increases in several integrin transcripts in pregnant myometrium. At the protein level, integrins such as α5-integrin (ITGA5), ITGA7, ITGAV, and ITGB3 were significantly increased during pregnancy. The integrins ITGA3, ITGA5, ITGA7, and ITGB1 colocalized with focal adhesion proteins in term human myometrium. These data suggest that integrins α3β1, α5β1, and α7β1 are the most likely candidates to transmit mechanical signals from the extracellular matrix through focal adhesions in pregnant human myometrium.


  • Expression, localization, and functional properties of Bestrophin 3 channel isolated from mouse heart

    by Kate E. O'DRiscoll, William J. Hatton, Heather R Burkin, Normand Leblanc, Fiona C. Britton

    Bestrophins are a novel family of proteins that encode calcium-activated chloride channels. In this study we establish that Bestrophin transcripts are expressed in the mouse and human heart. Native mBest3 protein expression and localization in heart was demonstrated by using a specific polyclonal mBest3 antibody. Immunostaining of isolated cardiac myocytes indicates that mBest3 is present at the membrane. Using the patch-clamp technique, we characterized the biophysical and pharmacological properties of mBest3 cloned from heart. Whole cell chloride currents were evoked in both HEK293 and COS-7 cells expressing mBest3 by elevation of intracellular calcium. mBest3 currents displayed a KDfor Ca2+of ∼175 nM. The calcium-activated chloride current was found to be time and voltage independent and displayed slight outward rectification. The anion permeability sequence of the channel was SCN−>I−>Cl−, and the current was inhibited by niflumic acid and DIDS in the micromolar range. In addition, we generated a site-specific mutation (F80L) in the putative pore region of mBest3 that significantly altered the ion conduction and pharmacology of this channel. Our functional and mutational studies examining the biophysical properties of mBest3 indicate that it functions as a pore-forming chloride channel that is activated by physiological levels of calcium. This study reports novel findings regarding the molecular expression, tissue localization, and functional properties of mBest3 cloned from heart.


  • Placental Defects in α7 Integrin Null Mice

    by J.V. Welser, N.D. Lange, N. Flintoff-Dye, H.R. Burkin, D.J. Burkin